Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17208358 | 0.77 | MLYCD (0.41) | MEN1KMT2ATSHRMLYCD | |
| SCHEMBL27848104 | 0.74 | KMT2A (0.36) | MEN1KMT2ATSHRMLYCD | |
| SCHEMBL23965315 | 0.74 | KMT2A (0.36) | MEN1KMT2ATSHRMLYCD | |
| SCHEMBL23109985 | 0.70 | CA12 (0.31) | MEN1KMT2A | |
| SCHEMBL23109987 | 0.68 | MEN1 (0.34) | MEN1KMT2ATSHR | |
| SCHEMBL13897445 | 0.67 | TSHR (0.40) | MEN1KMT2ATSHR | |
| SCHEMBL23156918 | 0.67 | — | — | |
| SCHEMBL2909351 | 0.66 | MGAM (0.46) | MEN1KMT2ATSHR | |
| SCHEMBL27488643 | 0.66 | TSHR (0.43) | MEN1KMT2ATSHR | |
| SCHEMBL13797928 | 0.66 | CA14 (0.45) | MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957518-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8252895-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-7872097-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20090170755-A1 | Cyclic Peptide Compounds | ASTELLAS PHARMA INC. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170755-A1 | Cyclic Peptide Compounds | VIP, HAVCR2, EIF2AK2 | MEN1 3591/4885KMT2A 3969/4885TSHR 2777/4885 |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, EIF2AK2 | MEN1 3864/4885KMT2A 4151/4885TSHR 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.